MAUNA KEA TECH : Mauna Kea Technologies Announces That 50 Scientific Articles Published on Cellvizio® in 2011 Underscore the Value of Endomicroscopy

Data show that adding cellular-level imaging to standard endoscopy procedures opens the possibility of improved cancer detection and treatment algorithms

Regulatory News:

Mauna Kea Technologies (Paris:MKEA) (NYSE Euronext: MKEA), the leader in the endomicroscopy market, today announced that 50 peer-reviewed scientific articles published on Cellvizio® during 2011 underscore the value of adding cellular-level imaging to endoscopy procedures. The publications, which include 35 on clinical applications, show the strong interest towards endomicroscopic imaging with Cellvizio.

These publications underscore the enormous progress of the medical community in the understanding of endomicroscopy applications for better diagnosis and more appropriate individualized patient care - in gastroenterology and pulmonology, as well as newer investigational applications such as urology. .

"Thanks to this small, flexible microscope, we can reach places that were previously difficult to access," explained Vani Konda, MD, a gastroenterologist at the University of Chicago Medical Center who has used Cellvizio since 2008. "We now benefit from a large body of clinical research work performed in the gastrointestinal field with Cellvizio. It helps us understand how endomicroscopy with probe-based techniques can improve our real-time assessment of regions of interest and pathologies during the endoscopy examination. With this advanced imaging technology, we are able to provide our patients with more accurate diagnoses and faster, more appropriate treatments."

The complete listing of published clinical studies with Cellvizio® is available on Mauna Kea Technologies' web site: http://www.maunakeatech.com/healthcare-professionals/445/bibliography

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company and a leader in endomicroscopic innovation. The company designs, develops and markets innovative tools to visualize and help detect abnormalities in the gastrointestinal and pulmonary tracts. Its flagship product (Cellvizio®, a probe-based confocal laser endomicroscopy (pCLE) system) provides physicians and researchers with high-resolution cellular views of tissue inside the body. Large, international, multicenter clinical trials have demonstrated Cellvizio®'s ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce hospital costs, Cellvizio can be used with almost any endoscope. Cellvizio® has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-Mark for use in the gastrointestinal and pulmonary tracts.
For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Next press release: 2012 financial agenda - January 5, 2012

United States
Erich Sandoval
Lazar Partners Ltd.
Tel: [phone]
[e-mail]
or
Mauna Kea Technologies
Alexander Bryson
Marketing Communications and Brand Manager
Tel: [phone]
[e-mail]
or
France and Europe
ALIZE RP
Caroline Carmagnol
Tel: + 33 1 42 68 86 43 / + 33 6 64 18 99 59
[e-mail]
Anne?Sophie Cosquéric
Tel: + 33 1 42 68 86 41 / [e-mail]
or
NewCap
Investor Relations and Financial Communication
Pierre Laurent / Florent Alba
Tel: [phone] / [e-mail]